Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.539
Filtrer
1.
Mol Pharm ; 21(10): 5071-5087, 2024 Oct 07.
Article de Anglais | MEDLINE | ID: mdl-39370819

RÉSUMÉ

The current study explores the effectiveness of drug particle deposition into human respiratory airways to cure various pulmonary-bound ailments. It has been assumed that drug solutions are inhaled in the form of tiny droplets or mist, which after striking create a thin layer along the inner surface of airways where the virus initially resides to infect the human body. A coupled Eulerian wall film (EWF) and discrete phase model (DPM) based simulation approach is used to capture these dynamics. Here, the Lagrangian DPM technique tracks the dynamics of tiny droplets, while the liquid layer formation after striking is captured using the Eulerian thin film approximations or the EWF model. Previous studies in this field primarily employed only the DPM method, which is inadequate to predict the poststriking dynamics of drug layer deposition and their spread to neutralize the respiratory virus. The drug delivery effectiveness is characterized by three different particle sizes, 1, 5, and 10 µm at the inhalation rates of 15, 30, and 60 L per minute (LPM). It has been found that the size of the drug particles significantly influences drug delivery effectiveness. The film thickness increases monotonically with particle sizes and inhalation rates. However, this increase in averaged film thickness is prominent in the range 5 to 10 µm (≈60%) compared to 1 to 5 µm (≈10%) droplet sizes at generation level 4 (G4). The other deposition parameters, e.g., deposition fraction, deposition density, and area coverage) roughly show similar behavior with the increase in droplet sizes. Therefore, it is recommended to vary the droplet sizes between 5 and 10 µm for better deposition effectiveness. The sizes of more than 10 µm mostly stuck into the oral cavity and cannot reach the targeted generations. In contrast, less than 5 µm may reach much deeper generations than the targeted one.


Sujet(s)
Taille de particule , Humains , Administration par inhalation , Systèmes de délivrance de médicaments/méthodes , Simulation numérique , Modèles biologiques , Poumon/métabolisme , Aérosols , Appareil respiratoire/métabolisme , Appareil respiratoire/virologie , Appareil respiratoire/effets des médicaments et des substances chimiques
2.
PLoS Pathog ; 20(7): e1012084, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38976749

RÉSUMÉ

Little is known about oxygen utilization during infection by bacterial respiratory pathogens. The classical Bordetella species, including B. pertussis, the causal agent of human whooping cough, and B. bronchiseptica, which infects nearly all mammals, are obligate aerobes that use only oxygen as the terminal electron acceptor for electron transport-coupled oxidative phosphorylation. B. bronchiseptica, which occupies many niches, has eight distinct cytochrome oxidase-encoding loci, while B. pertussis, which evolved from a B. bronchiseptica-like ancestor but now survives exclusively in and between human respiratory tracts, has only three functional cytochrome oxidase-encoding loci: cydAB1, ctaCDFGE1, and cyoABCD1. To test the hypothesis that the three cytochrome oxidases encoded within the B. pertussis genome represent the minimum number and class of cytochrome oxidase required for respiratory infection, we compared B. bronchiseptica strains lacking one or more of the eight possible cytochrome oxidases in vitro and in vivo. No individual cytochrome oxidase was required for growth in ambient air, and all three of the cytochrome oxidases conserved in B. pertussis were sufficient for growth in ambient air and low oxygen. Using a high-dose, large-volume persistence model and a low-dose, small-volume establishment of infection model, we found that B. bronchiseptica producing only the three B. pertussis-conserved cytochrome oxidases was indistinguishable from the wild-type strain for infection. We also determined that CyoABCD1 is sufficient to cause the same level of bacterial burden in mice as the wild-type strain and is thus the primary cytochrome oxidase required for murine infection, and that CydAB1 and CtaCDFGE1 fulfill auxiliary roles or are important for aspects of infection we have not assessed, such as transmission. Our results shed light on the environment at the surface of the ciliated epithelium, respiration requirements for bacteria that colonize the respiratory tract, and the evolution of virulence in bacterial pathogens.


Sujet(s)
Bordetelloses , Complexe IV de la chaîne respiratoire , Animaux , Souris , Complexe IV de la chaîne respiratoire/métabolisme , Complexe IV de la chaîne respiratoire/génétique , Bordetelloses/microbiologie , Infections de l'appareil respiratoire/microbiologie , Bordetella bronchiseptica/génétique , Bordetella bronchiseptica/métabolisme , Bordetella bronchiseptica/enzymologie , Humains , Appareil respiratoire/microbiologie , Appareil respiratoire/métabolisme , Évolution biologique , Bordetella/génétique , Bordetella/enzymologie , Bordetella pertussis/génétique , Bordetella pertussis/enzymologie , Protéines bactériennes/métabolisme , Protéines bactériennes/génétique
3.
Int J Pharm ; 661: 124408, 2024 Aug 15.
Article de Anglais | MEDLINE | ID: mdl-38969264

RÉSUMÉ

This paper presents a numerical investigation to understand the transport and deposition of sprays emitted by an impinging-jet inhaler in the human respiratory tract under different inhalation flow rates. An injection model is used for the numerical simulations considering the spreading angles of the spray in the two directions, which are measured from experiments. The model parameter is adjusted to match the mean droplet size measured in the previous experiment. A time-varying sinusoidal inhalation flow rate is utilized as airflow conditions, which is closer to the actual situation when using an inhaler. The results demonstrate that the inhalation airflow rate significantly affects the spray's transport behavior and deposition results in the respiratory tract. Both excessively high and low inhalation flow rates lead to an increase in deposition in the mouth-throat. A moderate inhalation flow rate reduces throat deposition while maximizing lung deposition. Higher inhalation flow rates enable faster delivery of the droplets to the lungs, whereas lower inhalation flow rates achieve a more uniform deposition over time in the lungs. The amount of deposition in different parts of the lung lobes follows a fixed order. This study provides valuable insights for optimizing the inhalation flow rate conditions of the impinging-jet inhaler for clinical applications.


Sujet(s)
Nébuliseurs et vaporisateurs , Humains , Administration par inhalation , Appareil respiratoire/métabolisme , Aérosols , Poumon/métabolisme , Taille de particule , Conception d'appareillage , Modèles biologiques , Simulation numérique
4.
J Hazard Mater ; 477: 135323, 2024 Sep 15.
Article de Anglais | MEDLINE | ID: mdl-39079294

RÉSUMÉ

Cadmium (Cd) poses a significant threat to human health. However, chronic toxicity parameters for inhalation exposure are lacking, especially for noncritical systemic toxic effects. A physiologically based toxicokinetic (PBTK) model can be used to extrapolate toxicity parameters across various exposure routes. We combined a PBTK model with a human respiratory tract (HRT) model, which is applicable to the general population and capable of simulating the deposition and clearance processes of various airborne Cd compounds in the respiratory tract. Monte Carlo analysis was used to simulate the distribution of sensitive parameters to reflect individual variability. Validation based on datasets from general and occupational populations showed that the improved model had acceptable or better predictive performance, outperforming the original model with a 14.45 % decrease in the root mean square error (RMSE). Using this PBTK-HRT model, we extrapolated toxicity parameters from oral exposure to inhalation exposure for four systemic toxic effects with doseresponse relationships but no known inhalation toxicity parameters, and ultimately recommended reference concentrations (RfCs) for four diseases (chronic kidney disease: 0.01 µg/m3, osteoporosis: 0.01 µg/m3, stroke: 0.04 µg/m3, diabetes mellitus: 0.13 µg/m3), contributing to a comprehensive assessment of the health risks of Cd inhalation exposure. ENVIRONMENTAL IMPLICATION: Cadmium (Cd), a heavy metal, can cause lung cancer, chronic kidney disease, and osteoporosis and pose a significant threat to human health. We combined a physiologically based toxicokinetic (PBTK) model with a human respiratory tract (HRT) model to achieve better predictive performance and wider applicability; this model was subsequently employed for route-to-route extrapolation of toxicity parameters. Additionally, for the first time, we focused on multiple subchronic and chronic systemic toxic effects in addition to critical effects and derived their reference concentrations (RfCs), which can be used to assess the health risk of Cd inhalation exposure more comprehensively and accurately.


Sujet(s)
Cadmium , Exposition par inhalation , Modèles biologiques , Appareil respiratoire , Toxicocinétique , Humains , Cadmium/toxicité , Cadmium/pharmacocinétique , Appareil respiratoire/effets des médicaments et des substances chimiques , Appareil respiratoire/métabolisme , Méthode de Monte Carlo
5.
Exp Physiol ; 109(8): 1370-1384, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38867461

RÉSUMÉ

Duchenne muscular dystrophy (DMD) is characterised by respiratory muscle injury, inflammation, fibrosis and weakness, ultimately culminating in respiratory failure. The dystrophin-deficient mouse model of DMD (mdx) shows evidence of respiratory muscle remodelling and dysfunction contributing to impaired respiratory system performance. The antioxidant N-acetylcysteine (NAC) has been shown to exert anti-inflammatory and anti-fibrotic effects leading to improved respiratory muscle performance in a range of animal models of muscle dysfunction, including mdx mice, following short-term administration (2 weeks). We sought to build on previous work by exploring the effects of chronic NAC administration (3 months) on respiratory system performance in mdx mice. One-month-old male mdx mice were randomised to receive normal drinking water (n = 30) or 1% NAC in the drinking water (n = 30) for 3 months. At 4 months of age, we assessed breathing in conscious mice by plethysmography followed by ex vivo assessment of diaphragm force-generating capacity. Additionally, diaphragm histology was performed. In separate studies, in anaesthetised mice, respiratory electromyogram (EMG) activity and inspiratory pressure across a range of behaviours were determined, including assessment of peak inspiratory pressure-generating capacity. NAC treatment did not affect force-generating capacity of the mdx diaphragm. Collagen content and immune cell infiltration were unchanged in mdx + NAC compared with mdx diaphragms. Additionally, there was no significant effect of NAC on breathing, ventilatory responsiveness, inspiratory EMG activity or inspiratory pressure across the range of behaviours from basal conditions to peak system performance. We conclude that chronic NAC treatment has no apparent beneficial effects on respiratory system performance in the mdx mouse model of DMD suggesting limited potential of NAC treatment alone for human DMD.


Sujet(s)
Acétylcystéine , Muscle diaphragme , Modèles animaux de maladie humaine , Souris de lignée mdx , Myopathie de Duchenne , Animaux , Acétylcystéine/pharmacologie , Myopathie de Duchenne/traitement médicamenteux , Myopathie de Duchenne/physiopathologie , Mâle , Souris , Muscle diaphragme/effets des médicaments et des substances chimiques , Muscle diaphragme/physiopathologie , Souris de lignée C57BL , Muscles respiratoires/effets des médicaments et des substances chimiques , Muscles respiratoires/physiopathologie , Respiration/effets des médicaments et des substances chimiques , Antioxydants/pharmacologie , Appareil respiratoire/effets des médicaments et des substances chimiques , Appareil respiratoire/physiopathologie , Appareil respiratoire/métabolisme
6.
Inhal Toxicol ; 36(6): 378-390, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38909354

RÉSUMÉ

OBJECTIVE: Cigarette smoking can lead to a host of adverse health effects such as lung and heart disease. Increased lung cancer risk is associated with inhalation of carcinogens present in a puff of smoke. These carcinogenic compounds deposit in the lung at different sites and trigger a cascade of events leading to adverse outcomes. Understanding the site-specific deposition of various smoke constituents will inform the study of respiratory diseases from cigarette smoking. We previously developed a deposition model for inhalation of aerosol from electronic nicotine delivery systems. In this study, the model was modified to simulate inhalation of cigarette smoke consisting of soluble and insoluble tar, nicotine, and cigarette-specific constituents that are known or possible human carcinogens. MATERIALS AND METHODS: The deposition model was further modified to account for nicotine protonation and other cigarette-specific physics-based mechanisms that affect smoke deposition. Model predictions showed a total respiratory tract uptake in the lung for formaldehyde (99%), nicotine (80%), and benzo[a]pyrene (60%). RESULTS: The site of deposition and uptake depended primarily on the constituent's saturation vapor pressure. High vapor pressure constituents such as formaldehyde were preferentially absorbed in the oral cavity and proximal lung regions, while low vapor pressure constituents such as benzo[a]pyrene were deposited in the deep lung regions. Model predictions of exhaled droplet size, droplet retention, nicotine retention, and uptake of aldehydes compared favorably with experimental data. CONCLUSION: The deposition model can be integrated into exposure assessments and other studies that evaluate potential adverse health effects from cigarette smoking.


Sujet(s)
Nicotine , Humains , Nicotine/administration et posologie , Nicotine/pharmacocinétique , Modèles biologiques , Fumée/analyse , Fumée/effets indésirables , Formaldéhyde/analyse , Formaldéhyde/toxicité , Produits du tabac/analyse , Benzo[a]pyrène/pharmacocinétique , Benzo[a]pyrène/analyse , Appareil respiratoire/effets des médicaments et des substances chimiques , Appareil respiratoire/métabolisme , Poumon/effets des médicaments et des substances chimiques , Poumon/métabolisme , Aérosols , Administration par inhalation , Exposition par inhalation/effets indésirables , Fumer des cigarettes , Dispositifs électroniques d'administration de nicotine
7.
Curr Opin Microbiol ; 80: 102505, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38936013

RÉSUMÉ

Commensal bacteria are residents of the human airway where they interact with both colonizing pathogens and host respiratory epithelial cells of this mucosal surface. It is here that commensals exert their influence through host signaling cascades, host transcriptional responses and host immunity, all of which are rooted in chromatin remodeling and histone modifications. Recent studies show that airway commensals impact host chromatin, but compared the what is known for gut commensals, the field remains in its infancy. The mechanisms by which airway commensals regulate respiratory health and homeostasis through chromatin modifications is of increasing interest, specifically since their displacement precedes the increased potential for respiratory disease. Herein we will discuss recent advances and intriguing avenues of future work aimed at deciphering how airway commensals protect and influence respiratory health.


Sujet(s)
Chromatine , Homéostasie , Humains , Chromatine/métabolisme , Chromatine/génétique , Animaux , Symbiose , Bactéries/métabolisme , Bactéries/génétique , Assemblage et désassemblage de la chromatine , Microbiote , Appareil respiratoire/microbiologie , Appareil respiratoire/immunologie , Appareil respiratoire/métabolisme
8.
Methods Mol Biol ; 2820: 165-185, 2024.
Article de Anglais | MEDLINE | ID: mdl-38941023

RÉSUMÉ

The upper respiratory tract (URT) is home to a diverse range of microbial species. Respiratory infections disturb the microbial flora in the URT, putting people at risk of secondary infections. The potential dangers and clinical effects of bacterial and fungal coinfections with SARS-CoV-2 support the need to investigate the microbiome of the URT using clinical samples. Mass spectrometry (MS)-based metaproteomics analysis of microbial proteins is a novel approach to comprehensively assess the clinical specimens with complex microbial makeup. The coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2) is responsible for the COVID-19 pandemic resulting in a plethora of microbial coinfections impeding therapy, prognosis, and overall disease management. In this chapter, the corresponding workflows for MS-based shotgun proteomics and metaproteomic analysis are illustrated.


Sujet(s)
COVID-19 , Co-infection , Protéomique , SARS-CoV-2 , Humains , COVID-19/virologie , COVID-19/complications , Protéomique/méthodes , Co-infection/microbiologie , Co-infection/virologie , SARS-CoV-2/isolement et purification , Microbiote , Infections de l'appareil respiratoire/microbiologie , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/diagnostic , Spectrométrie de masse/méthodes , Protéome/analyse , Appareil respiratoire/microbiologie , Appareil respiratoire/métabolisme , Appareil respiratoire/virologie
9.
Curr Opin Immunol ; 87: 102430, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38824869

RÉSUMÉ

Lambda interferons (IFNλs), also termed type III interferons (IFNs) or interleukins-28/29, have been in the shadow of type I IFNs for a long time. Their common induction mechanisms and signalling cascades with type I IFNs have made difficult the unwinding of their unique nonredundant functions. However, this is now changing with mounting evidence supporting a major role of IFNλs as a specialized antiviral defense system in the body, mediating protection at mucosal barrier surfaces while limiting immunopathology. Here, we review the latest progress on the complex activities of IFNλs in the respiratory tract, focusing on their multiple effects in IFNλ receptor-expressing cells, the modulation of innate and adaptive immune responses in the context of infections and respiratory diseases, and their similarities and differences with type I IFNs. We also discuss their potential in therapeutic applications and the most recent developments in that direction.


Sujet(s)
Immunité acquise , Immunité innée , Interféron lambda , Interférons , Appareil respiratoire , Humains , Animaux , Interférons/métabolisme , Interférons/immunologie , Appareil respiratoire/immunologie , Appareil respiratoire/métabolisme , Transduction du signal/immunologie , Interféron de type I/métabolisme , Interféron de type I/immunologie
10.
Biomed Pharmacother ; 177: 116984, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38908203

RÉSUMÉ

The global public health crisis caused by the COVID-19 pandemic has intensified the global concern regarding viral respiratory tract infections. Despite their considerable impact on health, society and the economy, effective management of these conditions remains a significant challenge. Integrating high-throughput analyses is pivotal for early detection, prognostication of adverse outcomes, elucidating pathogenetic pathways and developing therapeutic approaches. In recent years, microRNAs (miRNAs), a subset of small noncoding RNAs (ncRNAs), have emerged as promising tools for molecular phenotyping. Current evidence suggests that miRNAs could serve as innovative biological markers, aiding in informed medical decision-making. The cost-effective quantification of miRNAs in standardized samples using techniques routinely employed in clinical laboratories has become feasible. In this context, samples obtained from the airways represent a valuable source of information due to their direct exposure to the infectious agent and host response within the respiratory tract. This review explores viral and host miRNA profiling in airway-derived biosamples as a source of molecular information to guide patient management, with a specific emphasis on SARS-CoV-2 infection.


Sujet(s)
Marqueurs biologiques , COVID-19 , microARN , Infections de l'appareil respiratoire , SARS-CoV-2 , Humains , microARN/génétique , COVID-19/génétique , COVID-19/virologie , COVID-19/diagnostic , Infections de l'appareil respiratoire/virologie , Infections de l'appareil respiratoire/génétique , Infections de l'appareil respiratoire/diagnostic , Marqueurs biologiques/métabolisme , SARS-CoV-2/génétique , ARN viral/génétique , Appareil respiratoire/virologie , Appareil respiratoire/métabolisme
12.
Respir Physiol Neurobiol ; 326: 104271, 2024 08.
Article de Anglais | MEDLINE | ID: mdl-38703974

RÉSUMÉ

The objective of this study is to explore the transport, size growth, and deposition of Salbutamol Sulphate (SS) using Computational Fluid Dynamics (CFD). A CT-based realistic model of human airways from the oral cavity to the 5th generation of the lung was utilized as the computational domain. Four Test Cases (TC) with varying temperature and relative humidity (RH) under two inspiratory waveforms were considered to completely evaluate the impact of inhalation conditions on particle growth. Salbutamol Sulphate (SS) is a ß2-adrenergic agonist and has been extensively used for asthma treatment. A monodispersed distribution of SS particles with an initial diameter of 167 nm was considered at the mouth inlet based on pharmaceutical data. Results indicated that inhalation of saturated/supersaturated air (RH>100%) leads to significant hygroscopic growth of SS particles with a factor of 10. In addition, the deposition efficiency of SS particles under the Quick and Deep (QD) inhalation profile was enhanced as the flow temperature and humidity increased. However, the implementation of Slow and Deep (SD) inspiratory waveform revealed that the same particle size growth is achieved in the respiratory system with lower deposition efficiency in the mouth-throat (less than 3%) and tracheobronchial airway (less than 2.18%). For the escaped particles form the right lung, in the SD waveform under TC 3, the maximum particle size distribution was for 600 nm particles with 25% probability. In the left lung, 30% of the particles were increased up to 950 nm in size. For the QD waveform in TC 3 and TC4, the most frequent particles were 800 nm with 36% probability. This holds practical significance in the context of deep lung delivery for asthmatic patients with enhanced deposition efficiency and large particle size. The findings of the present study can contribute to the development of targeted drug delivery strategies for the treatment of pulmonary diseases using hygroscopic dry powder formulations.


Sujet(s)
Salbutamol , Simulation numérique , Humains , Salbutamol/administration et posologie , Salbutamol/pharmacologie , Administration par inhalation , Bronchodilatateurs/administration et posologie , Bronchodilatateurs/pharmacologie , Hydrodynamique , Modèles biologiques , Taille de particule , Humidité , Mouillabilité , Appareil respiratoire/effets des médicaments et des substances chimiques , Appareil respiratoire/métabolisme , Poumon/effets des médicaments et des substances chimiques , Poumon/métabolisme
13.
Pharm Dev Technol ; 29(5): 477-481, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38656248

RÉSUMÉ

This study was the first attempt to visualize pulmonary retention of nanocarriers (NCs) with the use of the P2 probe, a new water-initiated aggregation-caused fluorescent-quenching (ACQ) dye, for the development of NCs with long-lasting retention in the respiratory system (RS). Flash nanoprecipitation was used to fabricate mucopenetrating NCs (MP/NCs) and mucoadhesive NCs (MA/NCs). Both NCs were labeled with the P2 probe, and their distribution and retention in RS were visualized after intratracheal administration to rats. MP/NCs and MA/NCs had a mean diameter below 200 nm and ζ-potential of 0 and 48 mV, respectively. MA/NCs showed three times stronger interactions with mucin than MP/NCs, resulting in significantly lower diffusiveness in mucus. The P2 probe exhibited an ACQ effect with negligible rekindling in simulated lung fluid, and the spectroscopic data suggested applicability to reliable imaging of insufflated NCs. In confocal laser scanning microscopic and in vivo imaging system images of the rat RS, MA/NCs were locally deposited in the respiratory tract and transported toward the pharynx by mucocilliary clearance (MCC). In contrast, MP/NCs diffused in the respiratory mucus were less subject to the influence of MCC. Based on the results from the bioimaging study using the P2 probe, MP/NCs could offer enhanced pulmonary retention of drugs compared with MA/NCs.


Sujet(s)
Vecteurs de médicaments , Nanoparticules , Animaux , Rats , Nanoparticules/composition chimique , Vecteurs de médicaments/composition chimique , Mâle , Rat Sprague-Dawley , Appareil respiratoire/métabolisme , Appareil respiratoire/effets des médicaments et des substances chimiques , Colorants fluorescents/composition chimique , Colorants fluorescents/administration et posologie
14.
J Vis Exp ; (205)2024 Mar 22.
Article de Anglais | MEDLINE | ID: mdl-38587373

RÉSUMÉ

cAMP Difference Detector In Situ (cADDis) is a novel biosensor that allows for the continuous measurement of cAMP levels in living cells. The biosensor is created from a circularly permuted fluorescent protein linked to the hinge region of Epac2. This creates a single fluorophore biosensor that displays either increased or decreased fluorescence upon binding of cAMP. The biosensor exists in red and green upward versions, as well as green downward versions, and several red and green versions targeted to subcellular locations. To illustrate the effectiveness of the biosensor, the green downward version, which decreases in fluorescence upon cAMP binding, was used. Two protocols using this sensor are demonstrated: one utilizing a 96-well plate reading spectrophotometer compatible with high-throughput screening and another utilizing single-cell imaging on a fluorescent microscope. On the plate reader, HEK-293 cells cultured in 96-well plates were stimulated with 10 µM forskolin or 10 nM isoproterenol, which induced rapid and large decreases in fluorescence in the green downward version. The biosensor was used to measure cAMP levels in individual human airway smooth muscle (HASM) cells monitored under a fluorescent microscope. The green downward biosensor displayed similar responses to populations of cells when stimulated with forskolin or isoproterenol. This single-cell assay allows visualization of the biosensor location at 20x and 40x magnification. Thus, this cAMP biosensor is sensitive and flexible, allowing real-time measurement of cAMP in both immortalized and primary cells, and with single cells or populations of cells. These attributes make cADDis a valuable tool for studying cAMP signaling dynamics in living cells.


Sujet(s)
AMP cyclique , Appareil respiratoire , Humains , AMP cyclique/métabolisme , Isoprénaline/pharmacologie , Colforsine/pharmacologie , Cellules HEK293 , Appareil respiratoire/métabolisme
15.
Toxicology ; 504: 153781, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38493948

RÉSUMÉ

This comprehensive review focuses on various dimensions of nanoparticle toxicity, emphasizing toxicological characteristics, assessment techniques, and examinations of relevant studies on the effects on biological systems. The primary objective is to comprehend the potential risks associated with nanoparticles and to provide efficient strategies for mitigating them by consolidating current research discoveries. For in-depth insights, the discussions extend to crucial aspects such as toxicity associated with different nanoparticles, human exposure, and nanoparticle deposition in the human respiratory tract. The analysis utilizes the multiple-path particle dosimetry (MPPD) modeling for computational simulation. The SiO2 nanoparticles with a volume concentration of 1% and a particle size of 50 nm are used to depict the MPPD modeling of the Left upper (LU), left lower (LL), right upper (RU), right middle (RM), and right lower (RL) lobes in the respiratory tract. The analysis revealed a substantial 67.5% decrease in the deposition fraction as the particle size increased from 10 nm to 100 nm. Graphical representation emphasizes the significant impact of exposure path selection on nanoparticle deposition, with distinct deposition values observed for nasal, oral, oronasal-mouth breather, oronasal - normal augmenter, and endotracheal paths (0.00291 µg, 0.00332 µg, 0.00297 µg, 0.00291 µg, and 0.00383 µg, respectively). Consistent with the focus of the review, the article also addresses crucial mitigation strategies for managing nanoparticle toxicity.


Sujet(s)
Nanoparticules , Appareil respiratoire , Humains , Nanoparticules/toxicité , Appareil respiratoire/effets des médicaments et des substances chimiques , Appareil respiratoire/métabolisme , Animaux , Facteurs de risque , Exposition par inhalation/effets indésirables , Taille de particule , Appréciation des risques
16.
Cells ; 13(6)2024 Mar 07.
Article de Anglais | MEDLINE | ID: mdl-38534319

RÉSUMÉ

Chronic Obstructive Pulmonary Disease (COPD) is a pathological condition of the respiratory system characterized by chronic airflow obstruction, associated with changes in the lung parenchyma (pulmonary emphysema), bronchi (chronic bronchitis) and bronchioles (small airways disease). In the last years, the importance of phenotyping and endotyping COPD patients has strongly emerged. Metabolomics refers to the study of metabolites (both intermediate or final products) and their biological processes in biomatrices. The application of metabolomics to respiratory diseases and, particularly, to COPD started more than one decade ago and since then the number of scientific publications on the topic has constantly grown. In respiratory diseases, metabolomic studies have focused on the detection of metabolites derived from biomatrices such as exhaled breath condensate, bronchoalveolar lavage, and also plasma, serum and urine. Mass Spectrometry and Nuclear Magnetic Resonance Spectroscopy are powerful tools in the precise identification of potentially prognostic and treatment response biomarkers. The aim of this article was to comprehensively review the relevant literature regarding the applications of metabolomics in COPD, clarifying the potential clinical utility of the metabolomic profile from several biologic matrices in detecting biomarkers of disease and prognosis for COPD. Meanwhile, a complete description of the technological instruments and techniques currently adopted in the metabolomics research will be described.


Sujet(s)
Broncho-pneumopathie chronique obstructive , Humains , Broncho-pneumopathie chronique obstructive/métabolisme , Appareil respiratoire/métabolisme , Métabolomique/méthodes , Marqueurs biologiques/métabolisme , Spectrométrie de masse/méthodes
17.
Int J Mol Sci ; 25(3)2024 Feb 05.
Article de Anglais | MEDLINE | ID: mdl-38339210

RÉSUMÉ

The respiratory mucus, a viscoelastic gel, effectuates a primary line of the airway defense when operated by the mucociliary clearance. In chronic respiratory diseases (CRDs), such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF), the mucus is overproduced and its solid content augments, changing its structure and viscoelastic properties and determining a derangement of essential defense mechanisms against opportunistic microbial (virus and bacteria) pathogens. This ensues in damaging of the airways, leading to a vicious cycle of obstruction and infection responsible for the harsh clinical evolution of these CRDs. Here, we review the essential features of normal and pathological mucus (i.e., sputum in CF, COPD, and asthma), i.e., mucin content, structure (mesh size), micro/macro-rheology, pH, and osmotic pressure, ending with the awareness that sputum biomarkers (mucins, inflammatory proteins and peptides, and metabolites) might serve to indicate acute exacerbation and response to therapies. There are some indications that old and novel treatments may change the structure, viscoelastic properties, and biomarker content of sputum; however, a wealth of work is still needed to embrace these measures as correlates of disease severity in association with (or even as substitutes of) pulmonary functional tests.


Sujet(s)
Asthme , Mucoviscidose , Broncho-pneumopathie chronique obstructive , Troubles respiratoires , Humains , Mucus/métabolisme , Troubles respiratoires/métabolisme , Appareil respiratoire/métabolisme , Mucoviscidose/métabolisme , Asthme/métabolisme , Expectoration/métabolisme , Broncho-pneumopathie chronique obstructive/métabolisme , Mucines/métabolisme
18.
Life Sci Alliance ; 7(3)2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38176727

RÉSUMÉ

Activating transcription factor 4 (Atf4), which is modulated by the protein kinase RNA-like ER kinase (PERK), is a stress-induced transcription factor responsible for controlling the expression of a wide range of adaptive genes, enabling cells to withstand stressful conditions. However, the impact of the Atf4 signaling pathway on airway regeneration remains poorly understood. In this study, we used mouse airway epithelial cell culture models to investigate the role of PERK/Atf4 in respiratory tract differentiation. Through pharmacological inhibition and silencing of ATF4, we uncovered the crucial involvement of PERK/Atf4 in the differentiation of basal stem cells, leading to a reduction in the number of secretory cells. ChIP-seq analysis revealed direct binding of ATF4 to regulatory elements of genes associated with osteoblast differentiation and secretory cell function. Our findings provide valuable insights into the role of ATF4 in airway epithelial differentiation and its potential involvement in innate immune responses and cellular adaptation to stress.


Sujet(s)
Stress du réticulum endoplasmique , eIF-2 Kinase , Animaux , Souris , eIF-2 Kinase/génétique , Stress du réticulum endoplasmique/génétique , Facteur de transcription ATF-4/génétique , Facteur de transcription ATF-4/métabolisme , Différenciation cellulaire/génétique , Appareil respiratoire/métabolisme
19.
Am J Physiol Lung Cell Mol Physiol ; 325(6): L765-L775, 2023 12 01.
Article de Anglais | MEDLINE | ID: mdl-37847709

RÉSUMÉ

Airway mucociliary clearance (MCC) is required for host defense and is often diminished in chronic lung diseases. Effective clearance depends upon coordinated actions of the airway epithelium and a mobile mucus layer. Dysregulation of the primary secreted airway mucin proteins, MUC5B and MUC5AC, is associated with a reduction in the rate of MCC; however, how other secreted proteins impact the integrity of the mucus layer and MCC remains unclear. We previously identified the gene Bpifb1/Lplunc1 as a regulator of airway MUC5B protein levels using genetic approaches. Here, we show that BPIFB1 is required for effective MCC in vivo using Bpifb1 knockout (KO) mice. Reduced MCC in Bpifb1 KO mice occurred in the absence of defects in epithelial ion transport or reduced ciliary beat frequency. Loss of BPIFB1 in vivo and in vitro altered biophysical and biochemical properties of mucus that have been previously linked to impaired MCC. Finally, we detected colocalization of BPIFB1 and MUC5B in secretory granules in mice and the protein mesh of secreted mucus in human airway epithelia cultures. Collectively, our findings demonstrate that BPIFB1 is an important component of the mucociliary apparatus in mice and a key component of the mucus protein network.NEW & NOTEWORTHY BPIFB1, also known as LPLUNC1, was found to regulate mucociliary clearance (MCC), a key aspect of host defense in the airway. Loss of this protein was also associated with altered biophysical and biochemical properties of mucus that have been previously linked to impaired MCC.


Sujet(s)
Maladies pulmonaires , Clairance mucociliaire , Souris , Humains , Animaux , Clairance mucociliaire/physiologie , Appareil respiratoire/métabolisme , Mucus/métabolisme , Maladies pulmonaires/métabolisme , Souris knockout
20.
Expert Rev Respir Med ; 17(10): 903-917, 2023.
Article de Anglais | MEDLINE | ID: mdl-37905552

RÉSUMÉ

INTRODUCTION: Asthma is a chronic lung disease influenced by environmental and inflammatory triggers and involving complex signaling pathways across resident airway cells such as epithelium, airway smooth muscle, fibroblasts, and immune cells. While our understanding of asthma pathophysiology is continually progressing, there is a growing realization that cellular microdomains play critical roles in mediating signaling relevant to asthma in the context of contractility and remodeling. Mechanosensitive pathways are increasingly recognized as important to microdomain signaling, with Piezo and transient receptor protein (TRP) channels at the plasma membrane considered important for converting mechanical stimuli into cellular behavior. Given their ion channel properties, particularly Ca2+ conduction, a question becomes whether and how mechanosensitive channels contribute to Ca2+ microdomains in airway cells relevant to asthma. AREAS COVERED: Mechanosensitive TRP and Piezo channels regulate key Ca2+ regulatory proteins such as store operated calcium entry (SOCE) involving STIM and Orai channels, and sarcoendoplasmic (SR) mechanisms such as IP3 receptor channels (IP3Rs), and SR Ca2+ ATPase (SERCA) that are important in asthma pathophysiology including airway hyperreactivity and remodeling. EXPERT OPINION: Physical and/or functional interactions between Ca2+ regulatory proteins and mechanosensitive channels such as TRP and Piezo can toward understanding asthma pathophysiology and identifying novel therapeutic approaches.


Sujet(s)
Asthme , Calcium , Humains , Calcium/métabolisme , Signalisation calcique/physiologie , Appareil respiratoire/métabolisme , Membrane cellulaire/métabolisme , Asthme/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE